BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Téllez-Navarrete NA, Ramon-Luing LA, Muñoz-Torrico M, Preciado-García M, Medina-Quero K, Hernandez-Pando R, Chavez-Galan L. Anti-tuberculosis chemotherapy alters TNFR2 expression on CD4+ lymphocytes in both drug-sensitive and -resistant tuberculosis: however, only drug-resistant tuberculosis maintains a pro-inflammatory profile after a long time. Mol Med 2021;27:76. [PMID: 34261449 DOI: 10.1186/s10020-021-00320-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Liebenberg D, Gordhan BG, Kana BD. Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. Front Cell Infect Microbiol 2022;12:943545. [DOI: 10.3389/fcimb.2022.943545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 He T, Zhao Y, Zhao P, Zhao L, Zakaria J, Wang K. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4+Foxp3+ regulatory T cells. Int Immunopharmacol 2022;108:108823. [PMID: 35623290 DOI: 10.1016/j.intimp.2022.108823] [Reference Citation Analysis]
3 Druszczyńska M, Godkowicz M, Kulesza J, Wawrocki S, Fol M. Cytokine Receptors-Regulators of Antimycobacterial Immune Response. Int J Mol Sci 2022;23:1112. [PMID: 35163035 DOI: 10.3390/ijms23031112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]